Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT01783756
Title Phase 1b/2 Trial Using Lapatinib, Everolimus and Capecitabine for Treatment of HER-2 Positive Breast Cancer With CNS Metastasis
Recruitment Completed
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Jonsson Comprehensive Cancer Center
Indications

Her2-receptor positive breast cancer

Therapies

Capecitabine + Everolimus + Lapatinib

Age Groups: adult
Covered Countries USA


No variant requirements are available.